Raleigh, N.C., March 11, 2013 - INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced James Taylor has joined the Company as Vice President, Clinical Development. Mr. Taylor joins INC Research from Pfizer, where he served most recently as Vice President, Global Clinical Trial management. In his new role, Mr. Taylor will serve as the primary liaison to biopharmaceutical customers, vendors and investigative sites for the Company's General Medicine Business Unit.
"Jim is an accomplished leader with global experience across all phases of complex enterprise operations involving the execution of clinical trials," said Jamie Macdonald, CEO, INC Research. "Having worked in large pharma for many years, he brings a strong customer perspective, which allows him to anticipate our customers' needs and communicate their requirements more effectively. This insight, along with his unique blend of business and operational expertise, will be instrumental in further strengthening our relationships to drive innovation and accelerate decision making in clinical programs."
Mr. Taylor has more than 25 years of experience in the life sciences industry, including 15 years overseeing and executing global clinical trials. He also brings significant functional expertise in CRO selection and start-up, investigative site performance and contracting, CRO oversight and risk management, and alliance management from his experience at Pfizer where he oversaw the design, planning and execution of late stage clinical trials. Mr. Taylor's experience also includes serving as Global Head of outsourcing management at Sanofi-Aventis, where he was responsible for driving the global outsourcing strategy for its drug innovation and approval business unit.
About INC Research INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical developmentprograms of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: INC RESEARCH, LLC via Thomson Reuters ONE